EsoCap Publishes Positive Phase II Results for ESO-101 in Treating Eosinophilic Esophagitis

EsoCap AG has announced the publication of comprehensive Phase II results for ESO-101, demonstrating its effectiveness in treating eosinophilic esophagitis (EoE). Published in the journal Alimentary Pharmacology & Therapeutics, the ACESO study confirms that ESO-101 is safe, well tolerated, and improves both histologic and endoscopic outcomes in adults with active EoE.

The randomized, placebo-controlled study involved 43 participants across 14 centers in Europe. Results showed a significant reduction in eosinophil counts, with a mean drop of 49.1 eosinophils/hpf (p=0.0318) in the ESO-101 group. Remarkably, 48% of patients using ESO-101 reached <15 eosinophils/hpf, achieving notable histological remission, unlike the placebo group.

ESO-101, a unique drug delivery system, also demonstrated a high safety profile with no cases of candidiasis. EsoCap’s CEO, Isabelle Racamier, highlighted this publication as a milestone in advancing EoE treatment options.